Immuno-oncology

Biomarker assays, analysis and interpretations

Understanding the complexity of the tumour immune microenvironment in tissues from preclinical mouse models through to patients on clinical trial provides valuable information for the drug discovery process.

At HistologiX we offer validated and optimised IHC immuno-oncology biomarker assays, together with next generation quantitative image analysis tools to deliver valuable immunological insight into tumour immune processes. Our robust approach to the identification, quantification, localisation, and spatial relationships of immuno-oncology biomarkers in tumour tissues, and the ability to interpret data from these assays, supports clients in making informed decisions for advancing their immunotherapeutic strategy to market.

Spatial distribution of immune cells within the tumour microenvironment is likely to be as important as the quantitative assessment of immune cell densities. By defining the interface between tumour and stroma, the profile of immune cell subsets on either side of the invasive margin can be quantified, specifically identification of tumour-infiltrating lymphocytes (TILs).

Significant insights can be made into the impact of immunotherapies on tumour immune processes and classification of different tumour types by direct interrogation of the tumour-immune interface.

We turn your Data into Decisions

HALO™ Digital Image Analysis

Spatial relationships

Immuno-Oncology Biomarkers

HistologiX offer assays for a range of commercially available immuno-oncology research biomarkers. Search our ever-growing list of biomarker assays below. Don’t see what you’re looking for? We can work with you to develop immuno-oncology biomarker assays for your specific biomarker. Get in touch to discuss your needs.  

IHC Biomarkers
Alpha smooth muscle actin antibody Cytokeratin 10
Anti-PD1 Cytokeratin 18 antibody
Anti-PGP 9.5 Epithelial sodium channel alpha antibody
Bcl-xL (54H6) Rabbit mAb ErbB 2 antibody
BCL2 Estrogen receptor alpha
Beclin 1 F4/80
Calponin Filaggrin antibody
Carbonic anyhydrase IX (CA9) Fox-P3
CD11b GFP
CD137
GLP1R
CD20 (EP459Y)(HRP)
Granzyme B
CD20 antibody - C-terminal Grelin-1
CD24
Human Fibroblasts (TE-7)
CD25 (IL-2)
IL-2
CD3
IL-33
CD31
IL-8
CD32B Ki67
CD38 antibody (SP149) C-terminal LC3B
CD4 Lck (Phospho Y505)
CD40 antibody Mannose receptor antibody (CD206)
CD56 MCL-1
CD8 MICA/B (F-6)
CD8a Muc 5B
CEBP alpha antibody NAK/TBK1
CFTR antibody Newcastle's Disease Virus
Cleaved caspase 3 NG2
Col I OPTN/Optineurin
Col III PD-L1
Col IV Phospho-Akt
CONFIRM anti-CD3 (2GV6) Podocin
CONFIRM anti-CD4 (SP35) Phospho-p38 MAPK (Thr180/Tyr182)
CONFIRM anti-CD45RO (UCHL-1) Progesterone Receptor antibody
CONFIRM anti-CD8 (SP57) PTEN antibody (Y184)
Cytokeratin 1 PTEN antibody (Y184)

Please see our IHC biomarkers for more targets in other pathways.

Main Office Location

Innovation Building, BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF

Satellite Office Location

Block 20, Alderley Park, Nether Alderley, Cheshire, SK10 4TG

Email

info@histologix.co.uk